Acknowledging the "measured and cautious approach" of India in responding to recent requests for compulsory licenses and the successes some companies in enforcing their patents in at the preliminary injunction stage, representative of Pharmaceutical Research and Manufacturers of America told members of the US International Trade Commission yesterday that barriers remain.
"Despite these potentially positive signs and sustained industry engagement, PhRMA and its member companies remain negatively impacted by India's barriers to US trade and investment, including its failure to respect IP rights", said Amiee Aloi, associate vice president, Pharmaceutical Research and Manufacturers of America (PhRMA).
"The Modi Government has also emphasised predictable decision-making, implementation of political commitments, transparency, and good governance - all factors that are consistent with a rules-based government open to dialogue and problem solving in partnership with stakeholders," he added.
At the same time significant unpredictability in IP protection and enforcement in India remain as no progress has been made in terms of meaningful policy change to address the challenges faced by the innovative biopharmaceutical industry in India or in tackling the true barriers to patient access to new medicines, Aloi said.
Changes are afoot in the country, with new administration and positive indicators that the government recognises intellectual property as an important element of India's overall economic future, said Michael Schlesinger of International Intellectual Property Alliance (IIPA).
"These changes should translate into significant new market opportunities for right holders", Schlesinger said.
Copyright piracy, regulatory barriers, and market access barriers inhibit the continued growth of domestic and foreign copyright stakeholders in India, he added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
